// App-Quantinova.ai

7552 : Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment Naive (TN) Waldenstrom macroglobulinemia (WM).

Researchers

Presenter

  • Jonas Paludo

Principal Investigators

  • Morie A. Gertz

  • Shaji Kumar

  • Rebecca L King

  • Robert A. Kyle

  • Francis Buadi

  • Suzanne R. Hayman

  • Thomas Matthew Habermann

  • David Dingli

  • Thomas E. Witzig

  • Angela Dispenzieri

  • Martha Lacy

  • Carrie A. Thompson

  • Ronald S. Go

  • Wilson I. Gonsalves

  • John Anthony Lust

  • S. Vincent Rajkumar

  • Stephen Maxted Ansell

  • Prashant Kapoor

Medical Centers

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Department of Internal Medicine, Mayo Clinic, Rochester, MN

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

  • Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Waldenstrom’s macroglobulinemia

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Rituximab

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved